Zenas BioPharma, Inc. Financing Cash Flow
Zenas BioPharma, Inc. (ZBIO) reported Financing Cash Flow of $475.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Zenas BioPharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $42.06M, a 2342.33% increase year-over-year.
- Zenas BioPharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $433.48M, a 437757.58% increase year-over-year.
- Zenas BioPharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $140.84M, a 7500.81% increase year-over-year.
- Zenas BioPharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $72.62M, a 68.96% decline year-over-year.
- Zenas BioPharma, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $215.28M, a 47.87% decline from fiscal 2024.
- Zenas BioPharma, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $412.96M, a 1952.88% increase from fiscal 2023.
- Zenas BioPharma, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $20.12M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $475.54M 10-Q · filed 2026-08-13 | $616.38M derived: sum of 3 quarters · filed 2026-08-13 | $689.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $433.48M 10-Q · filed 2026-05-13 | $574.32M derived: sum of 2 quarters · filed 2026-05-13 | $646.94M derived: sum of 3 quarters · filed 2026-05-13 | $648.66M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $140.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $213.46M derived: sum of 2 quarters · filed 2026-03-16 | $215.18M derived: sum of 3 quarters · filed 2026-08-13 | $215.28M 10-K · filed 2026-03-16 |
| 2025-09-30 | $72.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $74.34M derived: sum of 2 quarters · filed 2026-08-13 | $74.44M 10-Q · filed 2025-11-12 | $76.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.82M 10-Q · filed 2026-08-13 | $3.67M derived: sum of 3 quarters · filed 2026-08-13 | $237.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $99.00K 10-Q · filed 2026-05-13 | $1.95M derived: sum of 2 quarters · filed 2026-05-13 | $235.93M derived: sum of 3 quarters · filed 2026-05-13 | $413.67M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $235.83M derived: sum of 2 quarters · filed 2026-03-16 | $413.57M derived: sum of 3 quarters · filed 2026-03-16 | $412.96M 10-K · filed 2026-03-16 |
| 2024-09-30 | $233.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $411.72M derived: sum of 2 quarters · filed 2025-11-12 | $411.11M 10-Q · filed 2025-11-12 | $411.15M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $177.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $177.13M 10-Q · filed 2025-08-12 | $177.18M derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$614.00K 10-Q · filed 2025-05-15 | -$564.00K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $20.12M 10-K · filed 2025-03-11 | ||
| 2023-09-30 | $20.07M 10-Q · filed 2024-11-12 |